October 06, 2016
Families in multidistrict litigation over GlaxoSmithKline's anti-nausea drug Zofran on Thursday told a Massachusetts federal court that a 2016 label update shows that it was, in fact, possible to show additional warnings on a previous label beyond what had been approved by regulators, contrary to the company's assertions.
October 05, 2016
A set of parents in multidistrict litigation over GlaxoSmithKline’s anti-nausea drug Zofran struck back on Tuesday at a bid to include their suit in a consolidated dismissal motion, saying they’ve gone above and beyond to make sure certain of their documents were correctly filed.
February 22, 2016
GlaxoSmithKline urged a Massachusetts' federal court on Monday to require all plaintiffs in multidistrict litigation over anti-nausea drug Zofran to identify whether they used the brand-name drug or its generic equivalent, saying that doing so will allow the court to assess the viability of individual cases.
January 06, 2016
Families who claim that GlaxoSmithKline's "off label" promotion of its anti-nausea drug Zofran for morning sickness led to birth defects urged the Massachusetts federal judge overseeing the multidistrict litigation on Wednesday not to dismiss their claims, pointing to animal studies they say support their allegations.
October 13, 2015
The U.S. Judicial Panel on Multidistrict Litigation on Tuesday consolidated in Massachusetts district court a number of lawsuits alleging GlaxoSmithKline's "off label" promotion of its anti-nausea drug Zofran for morning sickness led to birth defects, saying five similar actions are pending in the court already, including the first-filed complaint.